Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
- DOI
- 10.3324/haematol.2023.283861
- Published
- 2024-07-01
- Container
- Haematologica
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3324/haematol.2023.283861,
title = {Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.},
author = {Xu L and Shadman M and Flinn IW and Levy MY and Porter R and Burke JM and Zafar SF and Cultrera JL and Misleh J and Kingsley EC and Yimer HA and Freeman B and Chaudhry A and Tumula PK and Gandhi MD and Crescenzo R and By K and Cohen A and Chen DY and Idoine A and Manda S and Sharman JP and Ramakrishnan V.},
year = {2024},
journal = {Haematologica},
doi = {10.3324/haematol.2023.283861},
url = {https://doi.org/10.3324/haematol.2023.283861}
}RIS
TY - JOUR TI - Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies. AU - Xu L AU - Shadman M AU - Flinn IW AU - Levy MY AU - Porter R AU - Burke JM AU - Zafar SF AU - Cultrera JL AU - Misleh J AU - Kingsley EC AU - Yimer HA AU - Freeman B AU - Chaudhry A AU - Tumula PK AU - Gandhi MD AU - Crescenzo R AU - By K AU - Cohen A AU - Chen DY AU - Idoine A AU - Manda S AU - Sharman JP AU - Ramakrishnan V. PY - 2024 JO - Haematologica DO - 10.3324/haematol.2023.283861 UR - https://doi.org/10.3324/haematol.2023.283861 ER -
APA
L, X., M, S., IW, F., MY, L., R, P., JM, B., SF, Z., JL, C., J, M., EC, K., HA, Y., B, F., A, C., PK, T., MD, G., R, C., K, B., A, C., DY, C., A, I., S, M., JP, S., & V., R. (2024). Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.. Haematologica. https://doi.org/10.3324/haematol.2023.283861
Source records
- europe-pmc · retrieved 2026-09-26T02:14:50.154Z
- doaj · retrieved 2026-09-26T02:14:50.190Z